Aug, 2005

U.S.A.
News / Therapeutic Area News
Regadenoson Meets Primary Endpoint in First Phase 3 Trial
PALO ALTO, Calif. and DEERFIELD, IL, August 10, 2005 – CV Therapeutics, Inc. (Nasdaq: CVTX) and Astellas Pharma US, Inc. announced today that the first of two pivotal Phase 3 studies of...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Tarceva(R) to be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use in Pancreatic Cancer
MELVILLE, N.Y.--Aug. 8, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Oncologic Drugs Advisory Committee (ODAC) panel will review at its September 13, 2005 meeting the...
Read More

Jul, 2005

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Tarceva Granted Approval in Canada for the Treatment of Advanced Non-Small Cell Lung Cancer
MELVILLE, N.Y.--(BUSINESS WIRE)--July 13, 2005--OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) announced today that Health Canada has approved Tarceva® (erlotinib) for the treatment of patients with...
Read More

Jun, 2005

U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces that Tarceva-R- Receives Positive Opinion in EU for the Treatment of Patients with Advanced Lung Cancer
MELVILLE, N.Y.--(BUSINESS WIRE)--June 27, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced today that its ex- U.S. partner for Tarceva® (erlotinib), Roche, received a positive opinion from...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Issuance of Additional U.S. Patent for Tarceva; Extends Patent Exclusivity
MELVILLE, N.Y., Jun 02, 2005 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced the issuance of U.S. Patent No. 6,900,221 by the United States Patent and Trademark Office....
Read More